This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Ophthalmic disease

Glaucoma

MAP kinase kinase kinase 12 (MAP3K12; DLK)

Rodent studies suggest inhibiting DLK could have neuroprotective effects that help treat glaucoma. In a mouse model for optic nerve damage, deletion of Dlk in retinal ganglion cells decreased the loss of those cells by 75% compared with no deletion. In a rat model for intraocular pressure-induced glaucoma, pretreatment with tozasertib, an inhibitor of multiple kinases including DLK, prevented disease progression. Next steps could include developing more selective DLK inhibitors.
Tozasertib is a research reagent.

SciBX 6(9); doi:10.1038/scibx.2013.223
Published online March 7, 2013

Patent and licensing status unavailable

Welsbie, D.S. et al. Proc. Natl. Acad. Sci. USA; published online Feb. 19, 2013;
doi:10.1073/pnas.1211284110
Contact: Donald J. Zack, The Johns Hopkins University School of Medicine, Baltimore, Md.
e-mail:

dzack@jhmi.edu